In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi gets rights to Glenmark's TRPV3 antagonists for pain

Executive Summary

Glenmark Pharmaceuticals SA (division of Indian drug company Glenmark Pharmaceuticals Ltd.) has granted Sanofi-Aventis exclusive rights in certain countries to its transient receptor potential vanilloid receptor 3 (TRPV3) antagonists for chronic pain. The deal includes the Phase I candidate GRC15300 for diabetic neuropathic pain and osteoarthritic pain.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Marketing
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies